article thumbnail

Eli Lilly Claims Drug Prevents Coronavirus Infection in Nursing Homes

NY Times

A monoclonal antibody protected residents and staff members in facilities where the virus had appeared.

article thumbnail

Drug Prevents Coronavirus Infection in Nursing Homes, Maker Claims

NY Times

A monoclonal antibody protected residents and staff members in facilities where the virus had appeared.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How Can Nursing Homes Protect Themselves from COVID-19?

Pharma Mirror

This is because they often have weaker immune systems, so they can’t fight off a viral infection easily. The post How Can Nursing Homes Protect Themselves from COVID-19? Researchers have found that the elderly are particularly susceptible to the COVID-19 virus that caused the epidemic. This new situation puts.

article thumbnail

How Nursing Homes Get Paid and Why That Matters to LTC Pharmacy

Integra X Files

Many of you may be well acquainted with nursing home payment models – but a short primer can refocus us on important facts or familiarize colleagues newer to the industry. Let’s review how nursing homes get paid – and especially how that affects how pharmacies get paid for serving their residents. Areas of efficiency?

article thumbnail

Lilly’s antibody for COVID-19 protection starts nursing home trial

pharmaphorum

The US drugmaker is testing the antibody – called LY-CoV555 and developed in collaboration with Canadian biotech AbCellera – in a phase 3 trial to see if it can prevent the spread of the coronavirus among residents and staff in US nursing homes.

article thumbnail

The Use of Antipsychotic Drugs in Nursing Homes

NY Times

A professor, a psychiatrist and a nurse react to a Times investigation. Also: A modern Civil War; a more confident child.

article thumbnail

Coronavirus pharma news roundup – 07/08/20

pharmaphorum

The US drugmaker is testing the antibody – called LY-CoV555 and developed in collaboration with Canadian biotech AbCellera – in a phase 3 trial to see if it can prevent the spread of the coronavirus among residents and staff in US nursing homes.